Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927 is registered in ClinicalTrials.gov with Elisigen, Inc. as lead sponsor.

NCT NCT05984927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05984927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
Lead sponsor
Elisigen, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 8, 2023
Completion date
January 31, 2030
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration